At DSG, we work with leading consulting firms, CRO’s, non-profit organizations and technology service providers to ensure complete clinical trial solutions for our customers that are tailored to their needs. If you are interested in becoming a DSG partner or want to learn more, please contact us.
DupCheck is a web-based tool used globally to screen for duplicate patients in clinical trials across studies, sponsors and therapeutic areas. Duplicate enrollment harms both patients and studies.In many therapeutic areas even a small number of duplicate patients can lead to a negative or failed trial. In addition enrolling duplicate patients can result in a misattributed serious adverse event.
Learn more
finkyn is a service provider for the financial management of clinical trials. It's cloud-solution integrates with external EDC systems to fully automate site and patient payments. While you focus on advancing life-saving therapies, finklyn will eliminate administrative burdens and generates comprehensive insights into your global study budgets.
Learn more
Iron Mountain Incorporated (NYSE: IRM) is a global business dedicated to storing, protecting and managing, information and assets. Organizations across the globe trust us to store and protect information and assets. Thousands of local enterprises work with us, as does almost all of the FORTUNE 1000.
Learn more
We are a business that is passionate about communication amongst all people regardless of language, country of origin, or circumstance. We believe that communication is the first step to understanding. When we are understood we are empowered to exceed even our own expectations.
Learn more
Sungard AS partners with customers around the globe to understand their unique business needs and provide production and recovery services tailored to help them achieve their desired business outcomes. We apply our deep expertise and experience in disaster recovery to design, build and run production environments that are resilient and available in the present, and positioned for growth in the future.
Learn more